CINECA IRIS Institutional Research Information System

PELLEGRINI, CAROLINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.303
EU - Europa 2.544
AS - Asia 1.996
SA - Sud America 379
AF - Africa 149
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 9.376
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.199
IT - Italia 1.230
CN - Cina 634
SG - Singapore 570
HK - Hong Kong 374
BR - Brasile 337
SE - Svezia 275
DE - Germania 241
BG - Bulgaria 162
RU - Federazione Russa 124
GB - Regno Unito 105
FI - Finlandia 104
VN - Vietnam 95
AT - Austria 73
CI - Costa d'Avorio 65
FR - Francia 65
IN - India 64
CA - Canada 62
TR - Turchia 55
JP - Giappone 41
NL - Olanda 34
PL - Polonia 34
SN - Senegal 34
IR - Iran 22
UA - Ucraina 21
MX - Messico 19
BD - Bangladesh 17
PK - Pakistan 17
CZ - Repubblica Ceca 15
IQ - Iraq 14
AR - Argentina 13
BE - Belgio 13
KR - Corea 13
UZ - Uzbekistan 12
CH - Svizzera 11
SA - Arabia Saudita 11
EC - Ecuador 9
PH - Filippine 9
ZA - Sudafrica 8
PT - Portogallo 7
DZ - Algeria 6
ES - Italia 6
MA - Marocco 6
NG - Nigeria 6
VE - Venezuela 6
AE - Emirati Arabi Uniti 5
AZ - Azerbaigian 5
CO - Colombia 5
EG - Egitto 5
JM - Giamaica 5
KE - Kenya 5
LT - Lituania 5
MY - Malesia 5
PY - Paraguay 5
TW - Taiwan 5
PA - Panama 4
AU - Australia 3
DO - Repubblica Dominicana 3
GH - Ghana 3
IE - Irlanda 3
JO - Giordania 3
KG - Kirghizistan 3
LB - Libano 3
NO - Norvegia 3
PS - Palestinian Territory 3
RO - Romania 3
TN - Tunisia 3
TT - Trinidad e Tobago 3
AO - Angola 2
BJ - Benin 2
CL - Cile 2
DK - Danimarca 2
HU - Ungheria 2
MK - Macedonia 2
MO - Macao, regione amministrativa speciale della Cina 2
NI - Nicaragua 2
NP - Nepal 2
QA - Qatar 2
TH - Thailandia 2
UG - Uganda 2
AL - Albania 1
BH - Bahrain 1
BO - Bolivia 1
BS - Bahamas 1
BY - Bielorussia 1
CR - Costa Rica 1
CU - Cuba 1
GE - Georgia 1
GQ - Guinea Equatoriale 1
GT - Guatemala 1
HN - Honduras 1
ID - Indonesia 1
IL - Israele 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
NZ - Nuova Zelanda 1
OM - Oman 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
Totale 9.372
Salva come PNG Salva come JPEG
Città #
Ashburn 496
Fairfield 481
Santa Clara 395
Hong Kong 364
Woodbridge 329
Chandler 272
Singapore 236
Houston 225
Shanghai 205
Seattle 201
Wilmington 169
Cambridge 167
Milan 166
Sofia 160
Serra 156
New York 144
Ann Arbor 139
Pisa 125
Boardman 108
Beijing 96
Munich 94
Princeton 78
Florence 70
Los Angeles 69
Abidjan 65
Lawrence 59
Rome 54
Vienna 51
Dong Ket 48
Medford 47
Bremen 46
Turku 45
London 42
Ottawa 42
Lucca 41
Des Moines 40
Dakar 34
Frankfurt am Main 33
Lappeenranta 33
Montignoso 31
Istanbul 30
Ogden 27
Hefei 26
Chicago 25
Dearborn 25
Nanjing 24
Tokyo 23
Nuremberg 22
Redwood City 22
Naples 19
São Paulo 19
Pistoia 18
Warsaw 18
Bologna 17
Dallas 17
Livorno 16
Phoenix 14
Washington 14
Fuzhou 13
Marseille 13
San Diego 13
Kent 12
Tashkent 12
Brno 11
Brussels 11
Guangzhou 11
Helsinki 11
Padova 11
Rio de Janeiro 11
Shenzhen 11
Izmir 10
Nanchang 9
Toronto 9
Turin 9
Wuhan 9
Atlanta 8
Belo Horizonte 8
Changsha 8
Curitiba 8
Lancaster 8
Seoul 8
Aguascalientes 7
Council Bluffs 7
Dhaka 7
Montecatini Terme 7
Palermo 7
Quanzhou 7
Ancona 6
Brasília 6
Brescia 6
Campinas 6
Cascina 6
Chennai 6
Columbus 6
Hangzhou 6
Kunming 6
Lagos 6
New Delhi 6
Parma 6
Pune 6
Totale 6.386
Salva come PNG Salva come JPEG
Nome #
COMPOSTI INIBITORI DELL’INFLAMMASOMA NLRP3 E LORO USO 220
Protective Role of Flavonoids Against Colonic Motor Dysfunctions Associated with High Fat Diet-Induced Obesity 210
Histochemical Detection of Collagen Fibers by Sirius Red/Fast Green Is More Sensitive than van Gieson or Sirius Red Alone in Normal and Inflamed Rat Colon 202
A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation 182
Pathophysiology of NSAID-associated intestinal lesions in the rat: Luminal bacteria and mucosal inflammation as targets for prevention 178
Small bowel protection against NSAID-injury in rats: Effect of rifaximin, a poorly absorbed, GI targeted, antibiotic 168
NSAID-induced enteropathy: are the currently available selective COX-2 inhibitors all the same? 167
Colonic dysmotility associated with high-fat diet-induced obesity: Role of enteric glia 165
The AMPK enzyme-complex: from the regulation of cellular energy homeostasis to a possible new molecular target in the management of chronic inflammatory disorders 164
Colonic motor dysfunctions in a mouse model of high-fat diet-induced obesity: an involvement of A2B adenosine receptors 162
Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration 160
Enteric protective effects of the combination Bifidobacterium longum and lactoferrin in a rat model of diclofenac-induced intestinal injury. 159
Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients 155
The flavonoid compound apigenin prevents colonic inflammation and motor dysfunctions associated with high fat diet-induced obesity 149
Canonical and Non-Canonical Activation of NLRP3 Inflammasome at the Crossroad between Immune Tolerance and Intestinal Inflammation 146
The role of purinergic pathways in the pathophysiology of gut diseases: pharmacological modulation and potential therapeutic applications 144
Involvement of the P2X7 purinergic receptor in colonic motor dysfunction associated with bowel inflammation in rats 143
Prodromal Intestinal Events in Alzheimer's Disease (AD): Colonic Dysmotility and Inflammation Are Associated with Enteric AD-Related Protein Deposition 143
Mechanisms underlying the non-anticoagulant effects of apixaban and dabigatran on the integrity of intestinal mucosa: a comparative pre-clinical study. 141
AMPK Activators as Novel Drug Candidates for the Treatment of Inflammatory Bowel Diseases 138
Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications? 138
Luteolin Prevents Cardiometabolic Alterations and Vascular Dysfunction in Mice With HFD-Induced Obesity 137
Enteric dysfunctions in experimental Parkinson's disease: alterations of excitatory cholinergic neurotransmission regulating colonic motility in rats 136
Intestinal dysfunction in Parkinson's disease: Lessons learned from translational studies and experimental models 135
High Levels of β-Amyloid, Tau, and Phospho-Tau in Red Blood Cells as Biomarkers of Neuropathology in Senescence-Accelerated Mouse 133
Development of an Acrylate Derivative Targeting the NLRP3 Inflammasome for the Treatment of Inflammatory Bowel Disease 132
Protective effects of Saccharomyces boulardii CNCM I-745 Against Nonsteroidal anti-inflammatory drug-induced intestinal injury 131
Protective effects of the combination Bifidobacterium longum plus lactoferrin against NSAID-induced enteropathy 130
USP7 and USP47 deubiquitinases regulate NLRP3 inflammasome activation 128
Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration 128
Glial A2B Adenosine Receptors Modulate Abnormal Tachykininergic Responses and Prevent Enteric Inflammation Associated with High Fat Diet-Induced Obesity 127
Interplay between colonic inflammation and tachykininergic pathways in the onset of colonic dysmotility in a mouse model of diet-induced obesity 125
Anti-inflammatory effect of a novel locally acting A2A receptor agonist in a rat model of oxazolone-induced colitis. 123
Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases? 123
Preclinical development of fa5, a novel amp-activated protein kinase (Ampk) activator as an innovative drug for the management of bowel inflammation 123
The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis 121
Dietary flavonoids as a potential intervention to improve redox balance in obesity and related co-morbidities: a review 120
Dietary Supplement, Containing the Dry Extract of Curcumin, Emblica and Cassia, Counteracts Intestinal Inflammation and Enteric Dysmotility Associated with Obesity 119
Rifaximin Displays a Protective Activity in Experimental Enteropathy Induced by Indomethacin in Rats. 118
Donepezil improves vascular function in a mouse model of Alzheimer's disease 117
null 114
P2X7 receptor-dependent tuning of gut epithelial responses to infection 113
Constipation, deficit in colon contractions and alpha-synuclein inclusions within the colon precede motor abnormalities and neurodegeneration in the central nervous system in a mouse model of alpha-synucleinopathy 113
NLRP3 at the crossroads between immune/inflammatory responses and enteric neuroplastic remodelling in a mouse model of diet-induced obesity 110
Managing Obesity and Related Comorbidities: A Potential Pharmacological Target in the Adenosine System? 109
Role of the A(2B) receptor-adenosine deaminase complex in colonic dysmotility associated with bowel inflammation in rat 108
Adenosine signaling in the tumor microenvironment 108
null 103
Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology 102
Differential Impact of Weight Loss and Glycemic Control on Inflammasome Signaling 100
The intestinal barrier in disorders of the central nervous system 96
Dietary Supplementation with the Probiotic SF68 Reinforces Intestinal Epithelial Barrier in Obese Mice by Improving Butyrate Bioavailability 93
Neuronal regulation of intestinal immune functions in health and disease 92
Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration 91
Intestinal histomorphological and molecular alterations in patients with Parkinson's disease 90
Opioid receptors beyond pain control: The role in cancer pathology and the debated importance of their pharmacological modulation 90
Deepening the Mechanisms of Visceral Pain Persistence: An Evaluation of the Gut-Spinal Cord Relationship 90
Phytochemicals as Novel Therapeutic Strategies for NLRP3 Inflammasome-Related Neurological, Metabolic, and Inflammatory Diseases 89
Gastric motor dysfunctions in Parkinson's disease: Current pre-clinical evidence 86
Intestinal epithelial barrier and neuromuscular compartment in health and disease 86
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases 84
Use of Saccharomyces boulardii CNCM I-745 as therapeutic strategy for prevention of nonsteroidal anti-inflammatory drug-induced intestinal injury 83
- Medicament for preventing or treating irritable bowel syndrome or inflammatory bowel diseases 82
From the intestinal mucosal barrier to the enteric neuromuscular compartment: an integrated overview on the morphological changes in Parkinson's disease 82
The adenosine system at the crossroads of intestinal inflammation and neoplasia 78
Enteric glia at the crossroads between intestinal immune system and epithelial barrier: Implications for parkinson disease 77
Role of proteinase-activated receptors 1 and 2 in nonsteroidal anti-inflammatory drug enteropathy 75
Ectopic Lymphoid Organs and Immune-Mediated Diseases: Molecular Basis for Pharmacological Approaches 75
Role of cyclooxygenase pathways in bowel fibrotic remodelling in a murine model of experimental colitis 74
Enteric Glia and Brain Astroglia: Complex Communication in Health and Disease along the Gut-Brain Axis 71
NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications 66
Inflammatory Bowel Diseases: It's Time for the Adenosine System 65
The pharmacological blockade of P2X4 receptor as a viable approach to manage visceral pain in a rat model of colitis 63
NKG2A and COVID-19: another brick in the wall 63
Editorial: IBD Management—Novel Targets and Therapeutic Perspectives 58
Glomerular hyperfiltration in morbid obesity: Role of the inflammasome signalling 56
Author Correction: Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology (npj Parkinson's Disease, (2022), 8, 1, (9), 10.1038/s41531-021-00263-x) 56
Pharmacological modulation of P2X4 in inflammatory bowel diseases: the way towards novel therapeutics? 55
Gut-directed therapy in Parkinson’s disease 51
Pathological Remodeling of the Gut Barrier as a Prodromal Event of High-Fat Diet-Induced Obesity 50
LRRK2 is reduced in Parkinson’s disease gut 50
Lactiplantibacillus plantarum HEAL9 attenuates cognitive impairment and progression of Alzheimer's disease and related bowel symptoms in SAMP8 mice by modulating microbiota-gut-inflammasome-brain axis 46
Prokineticin-2 Is Highly Expressed in Colonic Mucosa of Early Parkinson's Disease Patients 43
Velusetrag rescues GI dysfunction, gut inflammation and dysbiosis in a mouse model of Parkinson's disease 42
LRRK2 expression in normal and pathologic human gut and in rodent enteric neural cell lines 38
Palmitoylethanolamide Counteracts Enteric Inflammation and Bowel Motor Dysfunctions in a Mouse Model of Alzheimer’s Disease 38
Enteric glial NLRP3 inflammasome contributes to gut mucosal barrier alterations in a mouse model of diet-induced obesity 36
Evaluation of the beneficial effects of a GABA-based product containing Melissa officinalis on post-inflammatory irritable bowel syndrome: a preclinical study 36
The administration of Enterococcus faecium SF68 counteracts compositional shifts in the gut microbiota of diet-induced obese mice 35
Adenosine signaling as target in cardiovascular pharmacology 33
Development of an adipocyte differentiation protocol using 3T3-L1 cells for the investigation of the browning process: identification of the PPAR-γ agonist rosiglitazone as a browning reference drug 31
Neuromuscular Function Abnormalities 30
Are LRRK2 mysteries lurking in the gut? 24
α-Synuclein in Parkinson's Disease: From Bench to Bedside 24
Gastrointestinal dysmotility in rodent models of Parkinson’s disease 21
Editorial: Neurological, Metabolic and Inflammatory Disorders: A Common Root in Inflammasome 20
Editorial: Reviews in neuropharmacology 2023: microbiota gut-brain axis, therapeutic insights for neurodegenerative diseases 15
How leaky is the gut in Parkinson’s disease? 5
Totale 9.754
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.655
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.655
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021765 61 61 67 32 43 33 31 53 102 119 39 124
2021/2022751 27 16 18 25 146 113 41 36 62 41 49 177
2022/20231.195 120 151 89 93 114 138 24 106 220 41 78 21
2023/20241.326 78 105 162 98 184 218 49 80 79 49 111 113
2024/20253.443 56 114 72 192 266 413 328 142 382 403 371 704
2025/202670 70 0 0 0 0 0 0 0 0 0 0 0
Totale 9.754